LENZ Therapeutics, Inc. LENZ
3.50 USD +0.49 (+16.28%)
At closeNov 6, 2026, 4:20 PM EST
3.50 0.00 0.00%
After hours · Nov 6, 4:20 PM ET
3.00 Day range 3.51
3.01 52-week range 31.94
- YTD
- -78.13%
- 1 year
- -84.76%
- Market cap
- 109.97M
- Revenue (ttm)
- 5.00M
- EPS (ttm)
- -4.53
- Shares out
- 30.27M
- Forward P/E
- -13.35
- YTD return
- -78.13%
- 1-year return
- -84.76%
- Volume
- 785.67K
- Avg volume
- 880.75K
- Open
- 3.00
- Previous close
- 3.01
- Day's range
- 3.00 – 3.51
- 52-week range
- 3.01 – 31.94
- Analysts
- Strong Buy
- Price target
- 54.25 (+1450.0%)
3M -1.86 (-34.70%)
Key statistics
- Enterprise value
- 724.20M
- PEG ratio
- 0.00
- Price / sales
- 189.98
- Price / book
- 4.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -28.96M
- Total cash
- 209.52M
- Total debt
- 1.05M
- Return on equity
- -26.25%
- Short % of float
- 34.22%
- 50-day average
- 40.93
- 200-day average
- 30.67
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 54.25 +1450.0% upside
Now 3.50
- Target (low)
- 36.00
- Target (mean)
- 54.25
- Target (high)
- 67.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy3
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.68908.
Financials — quick view
LENZ Revenue — quarterly 3.38M
LENZ Net income — quarterly -30.97M
LENZ EPS — quarterly -0.99
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2025 | Raymond James | reit | Outperform | Outperform |
| Oct 10, 2025 | Piper Sandler | main | Overweight | Overweight |
| Aug 1, 2025 | Citigroup | main | Buy | Buy |
| Aug 1, 2025 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 31, 2025 | Citigroup | main | Buy | Buy |
| Jul 31, 2025 | Raymond James | main | Outperform | Outperform |
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lenz-tx.com
News
Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $9 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $16 
TD Cowen Maintains Buy on LENZ Therapeutics, Lowers Price Target to $45 
LENZ Therapeutics Q3 2026 Earnings Call Transcript 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
LENZ Therapeutics Appoints CFO Dan Chevallard As Interim President, CEO, Effective Dec. 1, Succeeding Eef Schimmelpennink 
LENZ Therapeutics Q3 EPS $(0.99) Misses $(0.98) Estimate, Sales $3.384M Miss $4.200M Estimate - TD Cowen Maintains Buy on LENZ Therapeutics, Lowers Price Target to $50
- Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $5
Your note
Sign in to keep a note on LENZ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHEVALLARD DANIEL R | Chief Financial Officer | Purchase | May 13, 2024 | 3,188 |
| MCCOLLUM JAMES W | Director | Purchase | May 12, 2024 | 0 |
| ODRICH MARC | Officer | Stock Award(Grant) | Mar 20, 2024 | 99,599 |
| OLSSON SHAWN | Officer | Conversion of Exercise of derivative security | Apr 8, 2025 | 4,733 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Mar 20, 2024 | 0 |
| SCHIMMELPENNINK EVERT B. | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 6, 2025 | 49,200 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 14.65% | 4,178,823 | 131.13M | Jun 29, 2025 |
| Alpha Wave Global, LP | 12.66% | 3,612,211 | 113.35M | Jun 29, 2025 |
| Paradigm Biocapital Advisors LP | 6.02% | 1,717,066 | 53.88M | Jun 29, 2025 |
| Blackrock Inc. | 5.02% | 1,432,461 | 44.95M | Jun 29, 2025 |
| Vanguard Group Inc | 4.53% | 1,290,994 | 40.51M | Jun 29, 2025 |
| Adage Capital Partners GP L.L.C. | 3.94% | 1,122,738 | 35.23M | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.85% | 811,477 | 25.46M | Jun 29, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 1.40% | 398,938 | 12.52M | Sep 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.90% | 257,096 | 8.07M | Jun 29, 2025 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.63% | 178,821 | 5.61M | Jul 30, 2025 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.49% | 141,032 | 4.43M | Sep 29, 2025 |
| iShares Trust-iShares Biotechnology ETF | 0.49% | 138,483 | 4.35M | Sep 29, 2025 |